COST-CONSEQUENCE ANALYSIS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA

被引：0

作者：

Farhane, F. ^{[1
]}

Bhan, V ^{[2
]}

Clift, F. ^{[3
]}

Baharnoori, M. ^{[4
]}

Thomas, K. ^{[5
]}

Patel, B. P. ^{[5
]}

Blanchette, F. ^{[6
]}

Adlard, N. E. ^{[7
]}

Vudumula, U. ^{[8
]}

Gudala, K. ^{[9
]}

Dutta, N. ^{[5
]}

Grima, D. ^{[5
]}

Mouallif, S. ^{[6
]}

机构：

[1] Novartis Pharmaceut Canada Inc, Laval, PQ, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Mem Univ Newfoundland, St John, NB, Canada

[4] Queens Univ, Dept Med, Kingston, ON, Canada

[5] Eversana, Burlington, ON, Canada

[6] Novartis Pharmaceut Canada Inc, Montreal, PQ, Canada

[7] Novartis Pharma AG, Basel, Switzerland

[8] Novartis Ireland Ltd, Dublin, Ireland

[9] Novartis Healthcare Private Ltd, Hyderabad, Telangana, India

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE15

引用

页码：S55 / S56

页数：2